Nitzan Rosenfeld
Overview
Explore the profile of Nitzan Rosenfeld including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
11260
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Swalduz A, Schiffler C, Curcio H, Ambasager B, Le Moel G, Debieuvre D, et al.
J Thorac Oncol
. 2024 Dec;
PMID: 39694415
Objectives: Genomic profiling is a major component for first-line treatment decisions in patients with NSCLC and the timeliness of biomarker testing is essential to improve time to treatment initiation (TTI)...
2.
Jensen S, Moore D, Surani A, Crosbie P, Rosenfeld N, Rintoul R
J Thorac Oncol
. 2024 Dec;
19(12):e101-e102.
PMID: 39645301
No abstract available.
3.
Kwong F, Kristunas C, Davenport C, Deeks J, Mallett S, Agarwal R, et al.
Int J Gynecol Cancer
. 2024 Aug;
PMID: 39138005
Objective: Symptom-triggered testing for ovarian cancer was introduced to the UK whereby symptomatic women undergo an ultrasound scan and serum CA125, and are referred to hospital within 2 weeks if...
4.
Jensen S, Moore D, Surani A, Crosbie P, Rosenfeld N, Rintoul R
J Thorac Oncol
. 2024 Jul;
19(10):1415-1426.
PMID: 39059487
As a result of an increased focus on early detection including lung cancer screening, combined with more curative treatment options, the 5-year survival rates for lung cancer are improving. Welcome...
5.
Pope B, Park G, Lau E, Belic J, Lach R, George A, et al.
Eur Urol
. 2024 Feb;
85(4):407-410.
PMID: 38378299
No abstract available.
6.
Crispin-Ortuzar M, Woitek R, Reinius M, Moore E, Beer L, Bura V, et al.
Nat Commun
. 2023 Oct;
14(1):6756.
PMID: 37875466
High grade serous ovarian carcinoma (HGSOC) is a highly heterogeneous disease that typically presents at an advanced, metastatic state. The multi-scale complexity of HGSOC is a major obstacle to predicting...
7.
van Dorp J, Pipinikas C, Suelmann B, Mehra N, van Dijk N, Marsico G, et al.
Nat Med
. 2023 Jul;
30(1):304.
PMID: 37460757
No abstract available.
8.
Santonja A, Cooper W, Eldridge M, Edwards P, Morris J, Edwards A, et al.
EMBO Mol Med
. 2023 May;
15(6):e16505.
PMID: 37161793
Analysis of circulating tumor DNA (ctDNA) to monitor cancer dynamics and detect minimal residual disease has been an area of increasing interest. Multiple methods have been proposed but few studies...
9.
van Dorp J, Pipinikas C, Suelmann B, Mehra N, van Dijk N, Marsico G, et al.
Nat Med
. 2023 Feb;
29(3):588-592.
PMID: 36732628
Cohort 1 of the phase 1B NABUCCO trial showed high pathological complete response (pCR) rates with preoperative ipilimumab plus nivolumab in stage III urothelial cancer (UC). In cohort 2, the...
10.
Sauer C, Heider K, Belic J, Boyle S, Hall J, Couturier D, et al.
EMBO Mol Med
. 2022 Jun;
14(8):e15729.
PMID: 35694774
Whole-genome sequencing (WGS) of circulating tumour DNA (ctDNA) is now a clinically important biomarker for predicting therapy response, disease burden and disease progression. However, the translation of ctDNA monitoring into...